[go: up one dir, main page]

MX2018015873A - Preparacion de derivados del factor xa. - Google Patents

Preparacion de derivados del factor xa.

Info

Publication number
MX2018015873A
MX2018015873A MX2018015873A MX2018015873A MX2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A MX 2018015873 A MX2018015873 A MX 2018015873A
Authority
MX
Mexico
Prior art keywords
protein
derivatives
factor
preparation
chromatograph
Prior art date
Application number
MX2018015873A
Other languages
English (en)
Inventor
Karbarz Mark
B Conley Pamela
Genmin Lu
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60663351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018015873(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of MX2018015873A publication Critical patent/MX2018015873A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente descripción proporciona métodos para fabricar una proteína derivada de fXa a gran escala, lo que produce un alto rendimiento de producto proteico altamente puro. El método puede incluir agregar un detergente a una muestra que contiene una construcción de polinucleótidos que codifica la proteína y purifica la proteína a través de un cromatógrafo por afinidad basado en el inhibidor la tripsina de soja (STI), un cromatógrafo de modo mixto y de intercambio de iones y una interacción hidrofóbica.
MX2018015873A 2016-06-17 2017-06-19 Preparacion de derivados del factor xa. MX2018015873A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662351841P 2016-06-17 2016-06-17
PCT/US2017/038169 WO2017219034A2 (en) 2016-06-17 2017-06-19 Preparation of factor xa derivatives

Publications (1)

Publication Number Publication Date
MX2018015873A true MX2018015873A (es) 2019-08-12

Family

ID=60663351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018015873A MX2018015873A (es) 2016-06-17 2017-06-19 Preparacion de derivados del factor xa.

Country Status (21)

Country Link
US (4) US10604748B2 (es)
EP (3) EP4588932A3 (es)
JP (4) JP6959268B2 (es)
KR (1) KR102373215B1 (es)
CN (3) CN118271391A (es)
AU (2) AU2017283720C1 (es)
CL (2) CL2018003654A1 (es)
CO (1) CO2019000120A2 (es)
DK (1) DK3472314T3 (es)
EA (1) EA037815B1 (es)
ES (2) ES2875538T3 (es)
HU (1) HUE054597T2 (es)
IL (1) IL263591B2 (es)
MX (1) MX2018015873A (es)
PE (1) PE20190661A1 (es)
PH (1) PH12018502614A1 (es)
PL (1) PL3472314T3 (es)
PT (1) PT3472314T (es)
SG (1) SG11201810915QA (es)
SI (1) SI3472314T1 (es)
WO (1) WO2017219034A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3604510T3 (fi) * 2009-03-30 2025-06-26 Alexion Pharma Inc Vastalääkkeitä tekijä xa:n estäjille ja menetelmiä niiden käyttämiseksi
SG10201705189XA (en) * 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
MX2018015873A (es) * 2016-06-17 2019-08-12 Portola Pharm Inc Preparacion de derivados del factor xa.
US12195774B2 (en) 2018-06-19 2025-01-14 Alexion Pharmaceuticals, Inc. Antidotes to factor XA inhibitors
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189019A (en) * 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5589571A (en) * 1994-10-28 1996-12-31 Cor Therapeutics, Inc. Process for production of inhibited forms of activated blood factors
JPH1066572A (ja) * 1996-08-29 1998-03-10 Showa Sangyo Co Ltd 高純度の大豆トリプシンインヒビターの製造方法
US6376515B2 (en) 2000-02-29 2002-04-23 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor Xa
CN102336702B (zh) 2005-11-08 2015-02-11 米伦纽姆医药公司 Xa因子抑制剂n-(5-氯-2-吡啶基)-2-[[4-[(二甲氨基)亚氨基甲基]苯甲酰基]氨基]-5-甲氧基-苯甲酰胺的医药盐和多晶型
EP3078743B1 (en) 2007-09-28 2020-06-24 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
JP5709316B2 (ja) 2008-11-14 2015-04-30 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子阻害剤のための解毒剤および血液凝固剤と組み合わせて該解毒剤を使用する方法
FI3604510T3 (fi) * 2009-03-30 2025-06-26 Alexion Pharma Inc Vastalääkkeitä tekijä xa:n estäjille ja menetelmiä niiden käyttämiseksi
WO2011008885A1 (en) 2009-07-15 2011-01-20 Portola Pharmaceuticals, Inc. Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same
EP2861614B1 (en) * 2012-06-14 2016-11-30 Portola Pharmaceuticals, Inc. METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES
US20140346397A1 (en) * 2012-12-27 2014-11-27 Portola Pharmaceuticals, Inc. Compounds and methods for purification of serine proteases
SG10201705189XA (en) 2013-01-24 2017-07-28 Portola Pharm Inc INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES
MX373466B (es) * 2013-09-24 2020-05-25 Pfizer Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.
EA036091B1 (ru) * 2014-08-20 2020-09-25 Портола Фармасьютикалз, Инк. ВОДНЫЕ СОСТАВЫ АНТИДОТОВ ФАКТОРА Xa (fXa) ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ УМЕНЬШЕНИЯ КРОВОТЕЧЕНИЯ И ИХ ПРИМЕНЕНИЕ
MX2018015873A (es) * 2016-06-17 2019-08-12 Portola Pharm Inc Preparacion de derivados del factor xa.

Also Published As

Publication number Publication date
CL2018003654A1 (es) 2019-01-25
JP2026010692A (ja) 2026-01-22
AU2017283720C1 (en) 2024-07-25
AU2023200825A1 (en) 2023-03-16
US10604748B2 (en) 2020-03-31
PH12018502614A1 (en) 2019-09-30
PE20190661A1 (es) 2019-05-08
US20170369862A1 (en) 2017-12-28
SI3472314T1 (sl) 2021-11-30
SG11201810915QA (en) 2019-01-30
PL3472314T3 (pl) 2021-11-22
CN110167575A (zh) 2019-08-23
KR102373215B1 (ko) 2022-03-10
JP7273918B2 (ja) 2023-05-15
EA201990052A1 (ru) 2019-05-31
US20200208131A1 (en) 2020-07-02
EP3472314B1 (en) 2021-05-05
PT3472314T (pt) 2021-06-18
US10954504B2 (en) 2021-03-23
EA037815B1 (ru) 2021-05-25
JP2023086970A (ja) 2023-06-22
EP4588932A2 (en) 2025-07-23
WO2017219034A2 (en) 2017-12-21
WO2017219034A3 (en) 2019-03-14
JP2019528242A (ja) 2019-10-10
US20240076642A1 (en) 2024-03-07
IL263591A (en) 2019-02-03
CO2019000120A2 (es) 2019-03-29
IL263591B2 (en) 2023-03-01
AU2017283720A1 (en) 2019-01-03
EP4588932A3 (en) 2025-10-01
IL263591B (en) 2022-11-01
EP3926044A1 (en) 2021-12-22
CN116425860B (zh) 2025-03-04
DK3472314T3 (da) 2021-07-26
CN116425860A (zh) 2023-07-14
CN118271391A (zh) 2024-07-02
BR112018075964A2 (pt) 2019-04-02
KR20190019134A (ko) 2019-02-26
HUE054597T2 (hu) 2021-09-28
ES3038834T3 (en) 2025-10-15
JP2022000477A (ja) 2022-01-04
US20210348149A1 (en) 2021-11-11
EP3472314A4 (en) 2020-01-22
EP3472314A2 (en) 2019-04-24
EP3926044B1 (en) 2025-06-04
JP6959268B2 (ja) 2021-11-02
CN110167575B (zh) 2024-03-15
ES2875538T3 (es) 2021-11-10
AU2017283720B2 (en) 2022-11-17
CL2020001733A1 (es) 2020-09-25
CA3027457A1 (en) 2017-12-21
US11845966B2 (en) 2023-12-19

Similar Documents

Publication Publication Date Title
PH12018502614A1 (en) Preparation of factor xa derivatives
MX2018002831A (es) Polipeptidos.
NZ714079A (en) Purification process for monoclonal antibodies
MY193249A (en) Anti-human cd19 antibodies with high affinity
EP4375371A3 (en) Methods for the manufacture of proteolytically processed polypeptides
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
MX2021006732A (es) Nanoemulsiones para bebidas producidas mediante un proceso de alto cizallamiento.
MX2013014421A (es) Procedimiento para la preparacion de una composicion que comprende complejos metalicos en una matriz organica aceitosa.
NZ711192A (en) Process for making benzoxazepin compounds
MX2019015499A (es) Método para producir d-psicosa a partir de un complejo de borato y d-psicosa usando cromatografía y composición que contiene d-psicosa.
MX2018004299A (es) Metodo para la purificacion de ciclohexadec-8-en-1-ona.
MY195169A (en) Cyclic Ether Derivatives of Pyrazolo[1,5-A]Pyrimidine-3-Carboxyamide
BR112017025872A2 (pt) proteínas de ligação multiespecíficas
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
IN2013MU01113A (es)
GB2514940A (en) Process and method for the treatment of materials, materials thus obtained and uses of these materials
EA202190557A1 (ru) СПОСОБЫ ПОЛУЧЕНИЯ 4-{8-АМИНО-3-[(2S)-1-(БУТ-2-ИНОЛ)ПИРРОЛИДИН-2-ИЛ]ИМИДАЗО[1,5-a]ПИРАЗИН-1-ИЛ}-N-(ПИРИДИН-2-ИЛ)БЕНЗАМИДА
MX2015014193A (es) Metodo para separar y purificar lactoferrina humana recombinada a partir de semillas de arroz.
JO3712B1 (ar) طريقة لتحضير 1-(4-ميثان سلفونيل-2-تراي فلورو ميثيل-بنزيل)-2ميثيل-1h-بيرولو[2، 3-b]بيريدين-3-يل-حمض أسيتيك
EA201691510A1 (ru) Новые способы разделения горохового белка
EP4239329A3 (en) Method and apparatus
PH12014501220A1 (en) Removal of components from a starting material
NZ742210A (en) Neospora vaccine composition
JOP20190223A1 (ar) عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك